NCT01484275 2020-01-27
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
Clinical Trials
7 trialsNCT00401843 2019-11-19
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01219010 2015-01-19
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT00911859 2014-11-18
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Janssen Research & Development, LLC
Phase 2 Completed
NCT00412321 2014-07-01
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Centocor, Inc.
Phase 1 Completed
NCT01309412 2014-05-19
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Terminated
NCT00402181 2014-05-14
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 2 Completed